Herzzentrum Leipzig GmbH

The site focuses on reducing cardiovascular risk by targeting abnormal lipids and plaque formation. Use LDL‑cholesterol lowering strategies and novel agents to improve outcomes in patients with acute coronary syndromes and chronic atherosclerotic disease.

• Evolocumab therapy evaluation
• Pelacarsen for lipoprotein(a) reduction
• Inclisiran initiation in acute coronary settings
• Muvalaplin impact on major cardiovascular events

These studies aim to demonstrate superior prevention of death, myocardial infarction, stroke, or heart‑failure hospitalization compared with standard care.

Researchers investigate optimal platelet inhibition and anticoagulation for patients with atrial fibrillation, myocardial infarction, and post‑surgical arrhythmias. A focus on balancing clot prevention with bleeding risk is central to the work.

• Escalated P2Y12 inhibition after PCI
• Long‑term oral anticoagulation after catheter ablation
• Combination of oral anticoagulants with antiplatelet after CABG
• Reduced‑dose thrombolysis for intermediate‑high risk pulmonary embolism

The goal is to prove that intensified or combined regimens lower ischemic events without unacceptable bleeding.

The center evaluates new pharmacologic options to improve survival and quality of life for patients with chronic or acute decompensated heart failure. Trials include agents that modulate neuro‑hormonal pathways and sodium‑glucose transport.

• XXB750 dose‑response in symptomatic heart failure
• Empagliflozin continuation in acute decompensated heart failure
• Vicadrostat combined with empagliflozin in diabetics with heart disease
• NT‑proBNP reduction as a biomarker endpoint

Outcomes focus on reducing hospital readmissions, mortality, and renal decline.

A series of investigations target blood‑pressure control in patients with uncontrolled or resistant hypertension, including novel oral agents and dose‑titration strategies. The aim is to achieve sustained systolic reduction and organ protection.

• Lorundrostat efficacy and safety
• Randomized treatment‑withdrawal substudy of lorundrostat
• Long‑term maintenance of antihypertensive effect
• Impact on albuminuria and renal function

Successful trials could provide new options for patients who do not respond to conventional therapy.

Clinical work addresses the progression of calcific aortic valve stenosis and the role of myocardial fibrosis after transcatheter valve implantation. Researchers test anti‑fibrotic drugs to slow disease advancement.

• Pelacarsen effect on valve calcification and jet velocity
• Spironolactone ± Dihydralazine for post‑TAVI fibrosis regression
• Imaging endpoints using echocardiography and cardiac MRI

Reducing valve calcification and myocardial scarring may postpone surgical intervention and improve functional capacity.

Trials explore strategies to prevent acute kidney injury in patients undergoing major cardiac operations, aiming to preserve renal function and reduce postoperative complications.

• TIN816 impact on serum creatinine after surgery
• Cyclosporine A for myocardial injury with renal monitoring
• Biomarker‑guided assessment of kidney injury risk

Protecting the kidneys is expected to lower morbidity and support faster recovery after cardiac procedures.

The institution conducts studies on preventing and treating atrial fibrillation that arises after cardiac interventions, as well as its thrombo‑embolic consequences. Emphasis is placed on early anticoagulation and rhythm control.

• Oral anticoagulation vs. aspirin after catheter ablation
• Strategies to prevent stroke in atrial fibrillation patients
• Management of new‑onset postoperative atrial fibrillation after CABG

Demonstrating reduced stroke rates and hospitalizations would shape guideline recommendations for post‑operative care.